<DOC>
	<DOCNO>NCT01631383</DOCNO>
	<brief_summary>This study test safety pharmacokinetic profile l-THP cocaine exposure people history cocaine use . The subject admit Brief Stay Unit ( BSU ) , inpatient facility Maryland Psychiatric Research Center , use short term drug abuse clinical trial study . The participant stay 4 night 5 day . He/she randomize either placebo l-THP three day . On morning Day 4 , subject receive one cocaine dose ( 40 mg intranasal ) test pharmacokinetic parameter follow 10 hour . The subject stay one night discharge follow day . Approximately 40 subject randomize enroll target sample 30 ( N=15 placebo , N=15 l-THP ) . In summary , subject come screen visit ( ) , 5-day , 4-night stay secure research unit . After cocaine administration day , participant stay overnight one day observation permit substantial l-THP elimination body . The follow morning get one additional blood specimen l-THP ( Day 5 24 hour last dose ( 7:30 ) ; participant discharge . A visit blood collection Day 6 55 hour last dose ( 2:30 pm ) schedule . A final follow-up visit schedule 4-7 day unit discharge ensure persist side effect .</brief_summary>
	<brief_title>Pharmacokinetic Safety Evaluation L-tetrahydropalmatine ( l-THP ) With Cocaine Exposure People With History Cocaine Use</brief_title>
	<detailed_description />
	<mesh_term>Cocaine</mesh_term>
	<mesh_term>Tetrahydropalmatine</mesh_term>
	<criteria>Inclusion/ Inclusion criterion : 1. men nonpregnant/nonnursing woman age 18 50 year old 2. self report history cocaine use ( intranasal , IV smoke ) average least twice monthly least one month prior year 3. self report use least one use past six month cocaine dose equivalent 40 mg intranasal 15 mg smoke intravenous , base participant 's best estimate weight and/or street price amount ingest 4. positive urine drug test cocaine use least past 1 year 5 . HIV seronegative 6. hepatitis C seronegative 7 . EKG without clinically significant abnormality 8. normal blood pressure ( systolic : 90140 mmHg ; diastolic : 5090 mmHg ) rest heart rate ( 6090 bpm ) 9. within 20 % ideal body weight , base BJ Devine formula ( 1974 ) ( men : 50 + 2.3 kg per inch 5 foot , woman : 45.5 + 2.3 kg per inch 5 foot ) 10. ability adhere study restriction examination schedule 11 . Women reproductive potential must agree use one follow birth control method ( condom spermicide , diaphragm , intrauterine device ) study 2 week study conclusion . Exclusion criterion : 1. participation investigational drug trial clinical drug trial within 45 day study entry 2. donation loss great one pint blood within 60 day study entry 3. history clinically significant adverse reaction hypersensitivity study drug , 4. inability communicate cooperate investigator 5. treatmentseeking cocaine abuse/dependence 6. take concurrent prescription , counter medication , dietary/nutritional/herbal supplement ( St. John 's wort grapefruit juice , include standard vitamin mineral supplement ) within 14 day prior initial dosing . 7. current clinically significant medical problem might interfere safe study participation . This include pheochromocytoma , untreated hyperthyroidism , dehydration , fever , coronary artery disease , uncorrected congenital heart defect , seizure , electrolyte imbalance , uncontrolled diabetes mellitus , porphyria variegate , superventricular tachycardia , atrial fibrillation , cardiomyopathy , uncontrolled hypertension , . 8 . Current Axis I psychiatric disorder ( except nicotine dependence , cocaine abuse/dependence , simple phobia ) . Nicotine alter physiologic response cocaine ( Kouri et al 2001 ) 9 . Positive illicit drug cocaine marijuana urine drug screen 10 . Score 10/12 Evaluation Sign Consent ( ESC )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Cocaine Use</keyword>
</DOC>